

QUADRAMED CORP  
Form 10-Q  
November 07, 2008  
Table of Contents

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 10-Q**

(Mark One)

**Quarterly Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934  
FOR THE QUARTERLY PERIOD ENDED September 30, 2008**

Or

**Transition Report Pursuant To Section 13 Or 15(d) Of The Securities Exchange Act Of 1934  
FOR THE TRANSITION PERIOD FROM \_\_\_\_\_ TO \_\_\_\_\_**

**Commission File Number: 001-32283**

**QUADRAMED CORPORATION**

(Exact Name of Registrant as Specified in Its Charter)

Edgar Filing: QUADRAMED CORP - Form 10-Q

**DELAWARE**  
(State or Other Jurisdiction of

**52-1992861**  
(IRS Employer

Incorporation or Organization)

Identification No.)

**12110 SUNSET HILLS ROAD, SUITE 600**  
**RESTON, VIRGINIA**  
(Address of Principal Executive Offices)

**20190**  
(Zip Code)

**(703) 709-2300**

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated Filer

Non-accelerated Filer  (Do not check if a smaller reporting company)

Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

As of November 3, 2008, there were 8,287,259 shares of the Registrant's common stock outstanding, par value \$0.01.

**Table of Contents**

**QUADRAMED CORPORATION**  
**REPORT ON FORM 10-Q**  
**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**  
**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	
Item 1. <u>Financial Statements</u>	2
<u>Condensed Consolidated Balance Sheets (unaudited) as of September 30, 2008 and December 31, 2007</u>	2
<u>Condensed Consolidated Statements of Operations (unaudited) for the three and nine months ended September 30, 2008 and 2007</u>	3
<u>Condensed Consolidated Statements of Cash Flows (unaudited) for the three and nine months ended September 30, 2008 and 2007</u>	4
<u>Notes to Condensed Consolidated Financial Statements</u>	5
Item 2. <u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	26
Item 3. <u>Quantitative and Qualitative Disclosures About Market Risk</u>	38
Item 4. <u>Controls and Procedures</u>	39
<b><u>PART II. OTHER INFORMATION</u></b>	
Item 1A. <u>Risk Factors</u>	41
Item 6. <u>Exhibits</u>	41
<u>Signatures</u>	42

**Table of Contents****PART I. FINANCIAL INFORMATION****Item 1. Financial Statements**

**QUADRAMED CORPORATION**  
**CONDENSED CONSOLIDATED BALANCE SHEETS**

(in thousands, except per share amounts)

(unaudited)

	September 30, 2008	December 31, 2007
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	\$ 15,410	\$ 7,119
Short-term investments	5,210	9,169
Accounts receivable, net of allowance for doubtful accounts of \$1,088 and \$1,449, respectively	20,402	26,088
Unbilled receivables	9,679	5,183
Deferred contract expenses	5,608	6,060
Prepaid expenses and other current assets, net of allowance of \$919 and \$1,229, respectively	4,880	5,367
Deferred tax asset, net of valuation allowance	7,376	7,376
<b>Total current assets</b>	<b>68,565</b>	<b>66,362</b>
Restricted cash	1,556	2,389
Long-term investments	3,218	1,197
Property and equipment, net of accumulated depreciation and amortization of \$22,723, and \$22,855, respectively	3,166	3,778
Goodwill	35,632	33,942
Other amortizable intangible assets, net of accumulated amortization of \$29,110 and \$31,119, respectively	10,177	11,768
Other long-term assets	3,043	3,182
Deferred tax asset, net of valuation allowance	49,729	49,758
<b>Total assets</b>	<b>\$ 175,086</b>	<b>\$ 172,376</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current liabilities</b>		
Accounts payable and accrued expenses	\$ 5,477	\$ 4,910
Accrued payroll and related benefits	5,997	9,602
Accrued exit costs of facility closing	872	1,178
Other accrued liabilities	6,908	7,537
Dividends payable	1,375	1,375
Deferred revenue	44,733	36,111
<b>Total current liabilities</b>	<b>65,362</b>	<b>60,713</b>
Accrued exit cost of facility closing	227	888
Other long-term liabilities	1,883	2,722
<b>Total liabilities</b>	<b>67,472</b>	<b>64,323</b>
<b>Commitments, Contingencies and Subsequent Event</b>		
<b>Stockholders' equity</b>		
Preferred stock, \$0.01 par, 5,000 shares authorized, 4,000 shares issued and outstanding, respectively	96,144	96,144
Common stock, \$0.01 par, 30,000 shares authorized; 9,451 and 9,178 shares issued and 8,954 and 9,057 outstanding, respectively	99	459
Shares held in treasury, 497 and 121, respectively	(4,020)	(292)

## Edgar Filing: QUADRAMED CORP - Form 10-Q

Additional paid-in-capital	314,183	310,557
Accumulated other comprehensive loss	(504)	(80)
Accumulated deficit	(298,288)	(298,735)
<b>Total stockholders' equity</b>	107,614	108,053
<b>Total liabilities and stockholders' equity</b>	\$ 175,086	\$ 172,376

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents**

**QUADRAMED CORPORATION**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**

(in thousands, except per share amounts)

(unaudited)

	Three months ended, September 30,		Nine months ended, September 30,	
	2008	2007	2008	2007
<b>Revenue</b>				
Services	\$ 5,930	\$ 4,348	\$ 17,102	\$ 12,887
Maintenance	18,205	14,115	51,734	42,274
Installation and other	3,153	3,081	9,614	8,323
Services and other revenue	27,288	21,544	78,450	63,484
Term licences	8,099	8,485	23,651	22,093
Perpetual licenses	3,127	2,455	9,260	7,036
License revenue	11,226	10,940	32,911	29,129
Hardware	75	424	505	3,863
<b>Total revenue</b>	<b>38,589</b>	<b>32,908</b>	<b>111,866</b>	<b>96,476</b>
<b>Cost of revenue</b>				
Cost of services and other revenue	11,487	9,722	34,324	25,434
Royalties and other	3,671	4,237	11,365	11,273
Amortization of acquired technology and capitalized software	245		756	825
Cost of license revenue	3,916	4,237	12,121	12,098
Cost of hardware revenue	64	146	328	3,533
<b>Total cost of revenue</b>	<b>15,467</b>	<b>14,105</b>	<b>46,773</b>	<b>41,065</b>
<b>Gross margin</b>	<b>23,122</b>	<b>18,803</b>	<b>65,093</b>	<b>55,411</b>
<b>Operating expense</b>				
General and administration	5,027	4,464	14,907	12,916
Software development	8,328	8,144	25,362	23,218
Sales and marketing	4,968	4,536	14,105	12,345
Loss on sale of assets	46		1,161	
Amortization of intangible assets and depreciation	761	707	2,400	2,505
<b>Total operating expenses</b>	<b>19,130</b>	<b>17,851</b>	<b>57,935</b>	<b>50,984</b>
<b>Income from operations</b>	<b>3,992</b>	<b>952</b>	<b>7,158</b>	<b>4,427</b>
<b>Other income (expense)</b>				
Interest expense, includes non-cash charges of \$18, \$20 and \$54, \$104	(26)	(24)	(99)	(107)
Interest income	136	699	460	1,916
Other income, net	1	17	9	503

Edgar Filing: QUADRAMED CORP - Form 10-Q

<b>Other income, net</b>	111	692	370	2,312
<b>Income from operations before income taxes</b>	\$ 4,103	\$ 1,644	\$ 7,528	\$ 6,739
Provision for income taxes	(1,634)	(142)	(2,963)	(413)
<b>Net Income</b>	2,469	1,502	4,565	6,326
Preferred stock accretion, dividend premium, and dividend declared	(1,375)	(2,024)	(4,125)	(4,657)
<b>Net income (loss) attributable to common shareholders</b>	\$ 1,094	\$ (522)	\$ 440	\$ 1,669
<b>Income (loss) per share</b>				
Basic	\$ 0.12	\$ (0.06)	\$ 0.05	\$ 0.19
Diluted	\$ 0.12	\$ (0.06)	\$ 0.05	\$ 0.18
<b>Weighted average shares outstanding</b>				
Basic	8,931	8,769	8,930	8,776
Diluted	8,962	8,769	8,963	9,464

The accompanying notes are an integral part of these condensed consolidated financial statements.

**Table of Contents****QUADRAMED CORPORATION****CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**

(in thousands)

(unaudited)

	Three months ended September 30,		Nine months ended September 30,	
	2008	2007	2008	2007
<b>Cash flows from operating activities</b>				
Net income	\$ 2,469	\$ 1,502	\$ 4,565	\$ 6,326
Adjustments to reconcile net income to net cash provided by operating activities:				
Depreciation and amortization	1,006	707	3,157	3,331
Deferred compensation amortization	85	95	273	287
Dividend discount amortization		2		50
Stock-based compensation	805	807	2,445	1,546
Provision for bad debts	34		164	181
Loss on sale of assets	46		1,161	
Other	18	57	(16)	(32)
Changes in operating assets and liabilities:				
Accounts receivable	(1,835)	1,650	(3,861)	4,798
Prepaid expenses and other	3,583	(249)	1,247	2,935
Accounts payable and accrued liabilities	2,695	3,465	(5,294)	(1,035)
Deferred revenue	(6,081)	(4,013)	11,155	(539)
Cash provided by operating activities	2,825	4,023	14,996	17,848
<b>Cash flows from investing activities</b>				
Decrease (increase) in restricted cash	173	56	833	(38)
Purchases of available-for-sale securities	(190)	(13,278)	(4,220)	(46,691)
Proceeds from sale of available-for-sale securities	190	23,608	6,049	44,224
Payment of acquisition costs	(10)		(56)	
Purchases of property and equipment	(575)	(933)	(1,418)	(1,471)
Cash paid in the acquisition of the Computerized Patient Record business		(33,674)		(33,674)
Proceeds from sale of assets			106	
Cash (used in) provided by investing activities	(412)	(24,221)	1,294	(37,650)
<b>Cash flows from financing activities</b>				
Payment of preferred stock dividends	(1,375)	(1,375)	(4,125)	(4,253)
Proceeds from issuance of common stock and other	395	759	545	2,194
Repurchase of common stock			(3,727)	
Cash used in financing activities	(980)	(616)	(7,307)	(2,059)
<b>Effect of exchange rate changes on cash</b>	(626)	71	(692)	(6)
Net increase (decrease) in cash and cash equivalents	807	(20,743)	8,291	(21,867)
<b>Cash and cash equivalents, beginning of period</b>	14,603	31,472	7,119	32,596
<b>Cash and cash equivalents, end of period</b>	\$ 15,410	\$ 10,729	\$ 15,410	\$ 10,729
<b>Supplemental disclosure of cash flow information</b>				
Cash paid for taxes	96	32	410	514

The accompanying notes are an integral part of these condensed consolidated financial statements.



**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**1. THE COMPANY**

The business mission of QuadraMed Corporation, along with our subsidiaries ( QuadraMed or the Company ), is to advance the success of healthcare organizations through IT solutions that leverage quality care into positive financial outcomes. Our driving principles include: maintaining long-term client relationships, building a culture of customer care, focusing on innovation as the key to winning, and striving to always deliver value. We offer innovative, user-friendly software applications designed and developed by the healthcare professionals and software specialists we employ.

In the healthcare market, clinical information and quality measurements are becoming drivers of revenue management. Access management, financial decision support, health information management ( HIM ) processes and systems combined with patient accounting systems are driving revenue management improvements and the movement to new quality based reimbursement models. As evolving reimbursement scenarios will challenge hospitals to leverage quality of care into appropriate payment, we believe that customers committing to our Care-Based Revenue Cycle solutions will realize improved financial performance. Our goal is to assist our customers in attaining significant improvement in hospital financial success by leveraging quality of care into positive financial outcomes through performance-based IT solutions. We seek to accomplish this goal by delivering healthcare information technology products and services that support the healthcare organizations efforts to improve the quality of care they deliver and the efficiency with which it is delivered.

Using our end-to-end solutions to optimize the patient experience and leverage quality of care into payment, our clients seek to receive the proper reimbursement, in the shortest time, at the lowest administrative cost. Our products are designed to eliminate paper, improve processes, improve efficiencies and decrease error through the efficient management of patient clinical and financial records, resulting in better patient safety. Healthcare organizations of varying size from small single entity hospitals to large multi-facility care delivery organizations, acute care hospitals, specialty hospitals, the Department of Veterans Affairs facilities and associated/affiliated businesses such as outpatient clinics, long-term care facilities, and rehabilitation hospitals can gain value from our solutions.

We conduct business directly and through our subsidiaries, all of which are wholly owned and operated under common management. In September 2007, we acquired the Misys Computerized Patient Record business through an asset purchase. The Company considers itself to be a single reporting segment, specifically the software segment.

**2. SIGNIFICANT ACCOUNTING POLICIES**

**Financial Statement Presentation**

These condensed consolidated financial statements are unaudited and have been prepared in conformity with generally accepted accounting principles in the United States ( GAAP ) and pursuant to the rules and regulations of the Securities and Exchange Commission ( SEC ) regarding interim financial reporting. Accordingly, they do not include all of the information and disclosures required by accounting principles generally accepted in the United States for complete financial statements. We suggest that you read these interim financial statements in conjunction with the consolidated financial statements, and the notes thereto, included in the Company s Annual Report on Form 10-K for the year ended December 31, 2007, filed with the SEC on March 14, 2008. In the opinion of management, the condensed consolidated financial statements for the periods presented herein include all normal and recurring adjustments that are necessary for a fair presentation of the results for these interim periods. The results of operations for the three and nine months ended September 30, 2008 are not necessarily indicative of the results for the entire year ending December 31, 2008.

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**Principles of Consolidation and Basis of Presentation**

These condensed consolidated financial statements, which include the accounts of QuadraMed and all wholly owned subsidiaries, have been prepared in conformity with GAAP and the rules and regulations of the SEC. All significant intercompany accounts and transactions between QuadraMed and its subsidiaries are eliminated in consolidation.

Share and per share data (except par value) presented for all periods reflect the effect of a one-for-five reverse stock split effective on June 13, 2008, as discussed in Note 13 *Reverse Stock Split*. In addition, the number of shares of common stock issuable upon conversion of the Series A Preferred Stock, the exercise of outstanding stock options and the vesting of other stock awards, as well as the number of shares of common stock reserved for issuance under our various employee benefit plans, were proportionately adjusted in accordance with the terms of those respective agreements and plans.

**Use of Estimates in Preparation of Financial Statements**

We make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities, contingent assets and liabilities, revenues and expenses. Significant estimates and assumptions have been made regarding revenue recognition, the allowance for doubtful accounts, fair value measurement of financial instruments, contingencies, litigation, deferred revenue and intangibles resulting from our purchase business combinations, stock-based compensation and valuation allowance on deferred tax assets and other amounts. We base estimates and assumptions on historical experience and on various other assumptions which management believes to be reasonable under the circumstances. Uncertainties inherent in these estimates include, among other things, significant estimates within percentage-of-completion accounting. In addition, we review at least annually our estimates related to the valuations of intangibles including acquired technology, goodwill, customer lists, trademarks and other intangibles and capitalized software. Actual results may differ materially from these estimates and assumptions.

**Reclassifications**

Certain reclassifications have been made to prior year balances and categories of revenue and expense to conform them to the current year presentation.

**Revenue Recognition**

Our revenue is principally generated from licensing arrangements, services and hardware.

The Company's license revenue consists of fees for licenses of its proprietary software as well as the software of third-party providers. Cost of license revenue primarily includes the costs of third-party software, royalties and amortization of acquired technology and capitalized software. The Company's services revenue consists of maintenance, software installation, customer training and consulting services related to our license revenue, fees for providing management services, specialized staffing, and analytical services. Cost of services consists primarily of salaries, benefits and allocated costs related to providing such services. Hardware revenue includes third-party hardware used by our customers in connection with software purchased. Cost of hardware revenue consists of third-party equipment and installation.

We license products through a direct sales force. The Company's license agreements for such products do not provide for a right of return, and historically, product returns have not been significant.



**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

We recognize revenue on software products in accordance with AICPA Statement of Position ( SOP ) 97-2, *Software Revenue Recognition*, as amended; SOP 81-1, *Accounting for Performance of Construction-Type and Certain Production-Type Contracts*; and SEC Staff Accounting Bulletin ( SAB ) 104, *Revenue Recognition*.

We recognize revenue when all of the following criteria are met: there is persuasive evidence of an arrangement; the product has been delivered; we no longer have significant obligations with regard to implementation; the fee is fixed and determinable; and collectibility is probable. Delivery is considered to have occurred when title and risk of loss have been transferred to the customer, which generally occurs when media containing the licensed programs is provided to a common carrier. The Company considers all arrangements with payment terms extending beyond 180 days to be neither fixed nor determinable. Revenue for arrangements with extended payment terms is recognized when the payments become due, provided all other recognition criteria are satisfied. The Company typically defers revenue and recognizes revenue on a cash basis for renewals of term license and support if the Company's initial assessment is modified by facts and circumstances and collection is no longer deemed probable. Revenue may also be deferred and recognized on a cash basis if there is a contractual dispute and payments are delayed. Revenue is recognized when the collection becomes reasonably assured and/or the contract dispute is resolved.

We allocate revenue to each element in a multiple-element arrangement based on the element's respective fair value, with the fair value determined by the price charged when that element is sold separately. Specifically, we determine the fair value of the maintenance portion of the arrangement based on the price if sold separately and measured by the renewal rate offered to the customer. The professional services portion of the arrangement is based on hourly rates which we charge for these services when sold separately from software. If evidence of fair value of all undelivered elements exists but evidence does not exist for one or more delivered elements, then revenue is recognized using the residual method. Under the residual method, the fair value of the undelivered elements is deferred and the remaining portion of the arrangement fee is recognized as revenue. The proportion of revenue recognized upon delivery varies from quarter-to-quarter depending upon the mix of licensing arrangements, perpetual or term-based, and the determination of vendor-specific objective evidence ( VSOE ) of fair value for undelivered elements. Many of our licensing arrangements include fixed implementation fees and do not allow us to recognize license revenue until these services have been performed. We recognize revenue only after establishing that we have VSOE for all undelivered elements.

Some of the licenses are term or time-based licenses. We recognize revenue from these contracts ratably over the term of the arrangement. Post-contract Customer Support ( PCS ) for all of the license term is bundled together with the term license and is included in term license revenue in our consolidated financial statements.

Contract accounting is applied where services include significant software modification, installation or customization. In such instances, the services and license fee is accounted for in accordance with SOP 81-1, whereby the revenue is recognized, generally using the percentage-of-completion method measured on labor input hours. We use the completed-contract method of revenue recognition rather than the percentage-of-completion method for contracts with short implementation service periods (typically less than 3-9 months) and in circumstances in which the Company's financial position and results of operations would not vary materially from those resulting from the use of the percentage-of-completion method. If increases in projected costs-to-complete are sufficient to create a loss contract, the entire estimated loss is charged to operations in the period the loss first becomes known. The complexity of the estimation process and judgment related to the assumptions, risks and uncertainties inherent with the application of the percentage-of-completion method of accounting can affect the amounts of revenue and related expenses reported in the Company's

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

consolidated financial statements. The Company classifies revenues from these arrangements as license, installation, hardware, and services revenue based on the estimated fair value of each element using the residual method, and revenues are reflected in respective revenue categories in our consolidated financial statements.

Service revenues from software maintenance and support are recognized ratably over the maintenance term, which in most cases is one year. Service revenues from training, consulting and other service elements are typically recognized as the services are performed.

Hardware revenue is generated primarily from transactions in which customers purchase bundled solutions that included the Company's software and third-party hardware. If the bundled solution includes services that provide significant modification, installation or customization, contract accounting is applied in accordance with SOP 81-1, whereby the revenue is recognized, generally using the percentage-of-completion method measured on labor input hours. Otherwise, hardware revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, the fee is fixed or determinable and collection is reasonably assured.

Deferred revenue includes amounts billed to or received from customers for which revenue has not been recognized. This generally results from deferred maintenance, software installation, consulting and training services not yet rendered. License revenue is deferred until all revenue requirements have been met or as services are performed. Additionally, there are term-based licenses for which revenues are recognized over the term of the contract, which is generally one year. Unbilled receivables are established when revenue is deemed to be recognized based on our revenue recognition policy, however the Company does not have the right to bill the customer per the contract terms.

**Cash and Cash Equivalents**

Cash and cash equivalents are comprised principally of money market instruments and demand deposits with financial institutions. These instruments carry insignificant interest rate risk.

**Investments**

We account for our investments under SFAS No. 157, *Fair Value Measurements* ( SFAS No. 157 ) as partially adopted on January 1, 2008 for the year ending December 31, 2008. We consider our holdings of short-term and long-term securities, consisting primarily of fixed income securities to be available-for-sale securities. The difference between cost or amortized cost (cost adjusted for amortization of premiums and accretion of discounts that are recognized as adjustments to interest income) and fair value, representing unrealized holdings gains or losses, net of the related tax effect, if any, is recorded, until realized, as a separate component of stockholders' equity. Gains and losses on the sale of debt securities are determined on a specific identification basis. Realized gains and losses are included in other income (expense) in the accompanying Consolidated Statements of Operations.

The Company's investments include \$1.9 million of auction rate securities. Auction rate securities are collateralized long-term debt instruments that provide liquidity through a Dutch auction process that resets the applicable interest rate at pre-determined intervals, typically every 7 to 28 days. Since February 2008, auctions have failed for our holdings because sell orders have exceeded buy orders. During our third quarter, the brokers who originally sold us the auction rate securities entered into agreements with state and/or federal regulators to repurchase certain auction rate securities at par value. The Company notified the brokers it would participate in

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

the repurchase programs and in October 2008, \$1.2 million of our auction rate securities were sold at par under this program. The remaining \$0.7 million of our auction rate securities have been tendered for sale and our broker informed us the repurchase is expected to be completed in November 2008. Accordingly, the \$1.2 million of auction rate securities which were sold have been classified as short-term as of September 30, 2008. The remaining \$0.7 million that have been tendered for sale continue to be classified as long-term as of September 30, 2008 since the sale is not guaranteed under the repurchase program. Management believes that there has been no impairment of the carrying value of these investments.

**Accounts Receivable and Allowance for Doubtful Accounts**

Accounts receivable consist primarily of amounts due to QuadraMed from normal business activities. We provide an allowance for doubtful accounts to reflect the expected non-collection of accounts receivable based on past collection history and specific identified risks.

**Concentration of Credit Risk**

Accounts receivable represent our highest potential concentration of credit risk. We reserve for credit losses and do not require collateral on our trade accounts receivable. In addition, we maintain cash and investment balances in accounts at various domestic banks and brokerage firms. Our balances at banks are insured by the Federal Deposit Insurance Corporation. On October 3, 2008, President George W. Bush signed the Emergency Economic Stabilization Act of 2008, which temporarily raises the basic limit on federal deposit insurance coverage from \$100,000 to \$250,000 per depositor. The temporary increase in deposit insurance coverage became effective upon the President's signature. The legislation provides that the basic deposit insurance limit will return to \$100,000 after December 31, 2009.

**Property and Equipment**

Property and equipment are stated at cost and depreciated using the straight-line method over their estimated useful lives, which are generally three years for computer equipment and purchased software and five years for office furnishings and equipment. Leasehold improvements are amortized over the shorter of the term of the lease or the useful life (generally 10 years). Maintenance and repair costs are expensed as incurred. We review property and equipment for potential impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. For property and equipment sales and disposals, the cost and related accumulated depreciation are removed from the accounts and net amounts, less proceeds from disposals, are included in income.

**Goodwill**

We account for goodwill and other intangible assets in accordance with Statements of Financial Accounting Standards ( SFAS ) No. 142, *Goodwill and Other Intangible Assets* ( SFAS No. 142 ). Goodwill acquired in business combinations is not amortized but is tested for impairment annually or more often if an event or circumstances indicate that an impairment loss has been incurred. We have determined that we have one reporting unit under the criteria set forth by SFAS No. 142. We review goodwill for impairment in December of each year and as of December 31, 2007 determined that the fair value of the single reporting unit exceeded the carrying values of the net assets. Accordingly, no indicators of impairment existed.

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**Other Intangible Assets**

Other intangible assets primarily relate to customer lists, acquired technology including developed and core technology, trade names, and other intangible assets acquired in our purchase business combinations. On an annual basis, or upon the occurrence of a triggering event, we review our intangible assets for impairment based on estimated future undiscounted cash flows attributable to the assets in accordance with the provisions of SFAS No. 142, *Goodwill and Other Intangible Assets*. In the event such cash flows are not expected to be sufficient to recover the recorded value of the assets, the assets are written down to their net realizable values. Intangible assets are amortized over a period of two to ten years, which the Company estimated to reflect their useful lives.

**Software Development Costs**

In accordance with SFAS No. 86, *Accounting for the Costs of Computer Software to Be Sold, Leased or Otherwise Marketed*, we capitalize software development costs from establishment of technological feasibility to the point at which the product is generally available to the market.

**Income Taxes**

We account for income taxes in accordance with SFAS No. 109, *Accounting for Income Taxes* ( SFAS No. 109 ). Under SFAS No. 109, deferred tax assets and liabilities are computed based on the difference between the financial statement and income tax bases of assets and liabilities using the enacted marginal tax rate. SFAS No. 109 requires that the net deferred tax asset be reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some portion or all of the net deferred tax asset will not be realized.

This process requires us to make assessments regarding the timing and probability of the ultimate tax impact. We record valuation allowances on deferred tax assets if we determine it is more likely than not that the asset will not be realized. Additionally, we establish reserves for uncertain tax positions based upon our judgment regarding potential future challenges to those positions. Actual income taxes could vary from these estimates due to future changes in income tax law, significant changes in the jurisdictions in which we operate, our inability to generate sufficient future taxable income or unpredicted results from the final determination of each year's tax liability by taxing authorities. These changes could have a significant impact on our financial position.

The accounting estimate related to the tax valuation allowance requires us to make assumptions regarding the timing of future events, including the probability of expected future taxable income and available tax planning opportunities. These assumptions require significant judgment because actual performance has fluctuated in the past and may do so in the future. The impact that changes in actual performance versus these estimates could have on the realization of tax benefits as reported in our results of operations could be material.

We adopted Financial Accounting Standards Board ( FASB ) Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* ( FIN 48 ), on January 1, 2007. The accounting estimates related to liabilities for uncertain tax positions require us to make judgments regarding the sustainability of each uncertain tax position based on its technical merits. If we determine it is more likely than not that a tax position will be sustained based on its technical merits, we record the impact of the position in our consolidated financial statements at the largest amount that is greater than fifty percent likely of being realized upon ultimate settlement. These estimates are updated at each reporting date based on the facts, circumstances and information available. We are also required to assess at each reporting date whether it is reasonably possible that any significant increases or decreases to our unrecognized tax benefits will occur during the next twelve months. See Note 16 *Income Taxes*.

---

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**Sales Taxes**

In accordance with FASB's Emerging Issues Task Force (EITF) 06-3, *How Sales Taxes Collected from Clients and Remitted to Governmental Authorities Should Be Presented in the Income Statement (gross versus net presentation)*, we report sales taxes collected from clients and remitted to governmental authorities on a net basis.

**Accounting for and Disclosure of Guarantees and Indemnifications**

Our software license agreements generally include a performance guarantee that our software products will substantially operate as described in the applicable program documentation for a period of 90 days after delivery. We also generally warrant that services performed will be provided in a manner consistent with reasonably applicable industry standards. To date, we have not incurred any material costs associated with these warranties. Our software license agreements typically provide for indemnification of customers for claims for infringement of intellectual property. To date, no such claims have been filed against the Company.

**Stock-Based Compensation**

We adopted SFAS No. 123R, *Share-Based Payment* (SFAS No. 123R) using the modified prospective method as of January 1, 2006. Under this method, compensation cost is recognized based on the requirements of SFAS No. 123R for all share-based awards granted subsequent to January 1, 2006, and for all awards granted, but not vested, prior to January 1, 2006.

**Net Income (Loss) Per Share**

Basic income (loss) per share is determined using the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is determined using the weighted average number of common shares and common equivalent shares outstanding during the period. Common equivalent shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method) and conversion of preferred stock (using the as-converted method). Common equivalent shares are excluded from the diluted computation if their effect is anti-dilutive.

**3. RECENT ACCOUNTING PRONOUNCEMENTS**

In September 2006, EITF 06-4, *Accounting for Deferred Compensation and Postretirement Benefit Aspects of Endorsement Split-Dollar Life Insurance Arrangements*, (EITF 06-4) was issued and is effective for fiscal years beginning after December 15, 2007. EITF 06-4 requires that, for split-dollar life insurance arrangements that provide a benefit to an employee that extends to postretirement periods, an employer should recognize a liability for future benefits in accordance with SFAS No. 106. EITF 06-4 requires that recognition of the effects of adoption should be either by (a) a change in accounting principle through a cumulative-effect adjustment to retained earnings as of the beginning of the year of adoption or (b) a change in accounting principle through retrospective application to all prior periods. We adopted EITF 06-4 for the current year ending December 31, 2008 without any material impact to the financial statements.

In September 2006, the FASB issued SFAS No. 157, *Fair Value Measurements* (SFAS No. 157). SFAS No. 157 defines fair value, establishes a framework for measuring fair value in generally accepted accounting principles and expands disclosures about fair value measurements. SFAS No. 157 emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be



**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

determined based on the assumptions that market participants would use in pricing the asset or liability. The provisions of SFAS No. 157 are effective for fiscal years beginning after November 15, 2007 and interim periods within those fiscal years. In February 2008, the FASB issued a FASB Staff Position to partially delay the effective date of SFAS No. 157 for all non-financial assets and non-financial liabilities, except those that are recognized or disclosed at fair value in the financial statements on a recurring basis, until fiscal years beginning after November 15, 2008. Based on the FASB Staff Position, the partial adoption of SFAS No. 157 has not had a material impact on our financial position and results of operations for the year ending December 31, 2008. We are still assessing the impact that SFAS No. 157 will have on our nonrecurring measurements for non-financial assets and liabilities in 2009.

In February 2007, the FASB issued SFAS No. 159, *The Fair Value Option for Financial Asset and Financial Liability: Including an amendment to FASB Statement No. 115* ( SFAS No. 159 ). The standard permits all entities to elect to measure certain financial instruments and other items at fair value with changes in fair value reported in earnings. SFAS No. 159 is effective as of the beginning of the first fiscal year that begins after November 15, 2007. Although we adopted this standard for the current year ending December 31, 2008, we did not elect to measure our financial instruments at fair value and accordingly, its adoption did not have a material impact to the financial statements.

In December 2007, the FASB issued SFAS No. 141R, *Business Combinations* ( SFAS No. 141R ). SFAS No. 141R requires the acquiring entity in a business combination to record all assets acquired and liabilities assumed at their respective acquisition-date fair values, changes the recognition of assets acquired and liabilities assumed arising from contingencies, changes the recognition and measurement of contingent consideration, and requires the expensing of acquisition-related costs as incurred. SFAS No. 141R also requires additional disclosure of information surrounding a business combination, such that users of the entity's financial statements can fully understand the nature and financial impact of the business combination. SFAS No. 141R applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008, which is our fiscal year 2009. An entity may not apply SFAS No. 141R before that date. The provisions of SFAS No. 141R will generally only impact us if we are party to a business combination after the pronouncement has been adopted.

In December 2007, the FASB issued SFAS No. 160, *Noncontrolling Interests in Consolidated Financial Statements - An Amendment of ARB No. 51* ( SFAS No. 160 ). SFAS No. 160 establishes new accounting and reporting standards for the non-controlling interest in a subsidiary and for the deconsolidation of a subsidiary. SFAS No. 160 is effective for fiscal years beginning on or after December 15, 2008. We do not currently expect the adoption of SFAS No. 160 to have a material impact on our consolidated financial position, results of operations or cash flows.

**4. ACQUISITION OF THE MISYS COMPUTERIZED PATIENT RECORD BUSINESS**

On September 23, 2007, the Company, through QuadCopper, LLC, a Delaware limited liability company and indirect, wholly-owned subsidiary of the Company, completed its acquisition of substantially all of the Computerized Patient Record ( CPR ) assets and related business of Misys plc (the CPR Business ) pursuant to the previously announced asset purchase agreement (the Agreement ), dated July 22, 2007, by and among Misys plc, a company organized under the laws of the United Kingdom, Misys Hospital Systems, Inc., a Pennsylvania corporation and indirect wholly-owned subsidiary of Misys plc, QuadCopper LLC, and the Company. Pursuant to the terms of the Agreement, the Company paid \$33.0 million in cash for the CPR Business.

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)**

The total purchase price, including related acquisition costs of approximately \$1.0 million, was approximately \$34.0 million. The cash used by the Company to acquire the CPR Business came from the Company's available cash and the conversion of short term investments into cash. No gains or losses on the conversions were recorded as the investments were not sold prior to their maturity dates. The results of the CPR Business operations have been included in the consolidated financial statements since the date of the acquisition.

The following table summarizes the estimated fair values of the assets acquired and liabilities assumed at the date of acquisition including subsequent adjustments to the purchase accounting in accordance with SFAS No. 141, *Business Combinations* (in thousands):

Current assets acquired	\$ 10,582
Property and equipment	755
Identifiable intangible assets	12,400
Goodwill	13,881
Current liabilities	(3,439)
Long term liabilities-capital lease obligation	(222)
<b>Net Assets Acquired</b>	<b>\$ 33,957</b>

The goodwill recognized results primarily from the value of the clinical product features and functionality acquired, beyond its current features and functionality and that of the legacy Affinity clinical software that will allow us to compete for clinical information systems business in large hospitals and multi-facility engagements where we would otherwise not be able to compete. Goodwill increased by approximately \$1.7 million for the nine month period ended September 30, 2008 primarily due to the evaluation of deferred revenue on customer contracts acquired, a reduction of estimated commissions, and a reduction of accounts receivable offset by deferred contract costs realigned with remaining contract obligations and additional legal and professional fees. The purchase price allocation was finalized during the quarter ended September 30, 2008. The identifiable intangible assets include the following:

Trade Names (2 years straight line amortization)	\$ 300
Technology (10 years sum of years digits amortization)	5,400
Customer Relationships (10 years sum of years digits amortization)	6,700
Total identifiable intangible assets	\$ 12,400

**5. DISCONTINUED OPERATIONS****Division Shutdown and Headquarters Relocation**

We completed the shutdown of our Financial Services division in San Marcos, California on February 14, 2005. We estimated the facility closing costs in accordance with SFAS No. 146, *Accounting for Costs Associated with Exit or Disposal Activities*, as the master lease associated with this facility did not terminate until May 2008. In addition, we also vacated and closed our San Rafael, California facility during the fourth quarter of 2004 as a result of the relocation of our headquarters to Reston, Virginia. We estimated our liability under the operating lease agreement and accrued exit costs as the lease does not terminate until December 2009. Subsequently, we secured a sub-tenant for 33% of the space. However, the sub-tenant prematurely vacated the space in June 2008. As a result, the San Rafael lease payments to be made by

Edgar Filing: QUADRAMED CORP - Form 10-Q

QuadraMed total \$1.1 million for the remaining three months of 2008 and the year 2009, including the Company's share of common costs.

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)**

The following table sets forth a summary of the exit cost charges and accrued exit costs for both the San Marcos, California and San Rafael, California facilities as of September 30, 2008 and December 31, 2007 (in thousands):

	September 30, 2008	December 31, 2007
<i>Exit Costs for the San Rafael Facility:</i>		
Accrued exit cost of facility closing, beginning of period	\$ 1,931	\$ 3,079
Principal reductions	(832)	(1,148)
Accrued exit cost of facility closing, end of period	\$ 1,099	\$ 1,931
<i>Exit Cost for the San Marcus Facility:</i>		
Accrued exit cost of facility closing, beginning of period	\$ 135	\$ 534
Principal reductions	(135)	(399)
Accrued exit cost of facility closing, end of period	\$	\$ 135
<b>Total Exit Cost Charges and Accrued Exit Costs</b>	<b>\$ 1,099</b>	<b>\$ 2,066</b>
<i>Summary:</i>		
Accrued Exit Cost Liability		
Short-term	\$ 872	\$ 1,178
Long-term	227	888
Total	\$ 1,099	\$ 2,066

**6. SALE OF ASSETS**

On April 30, 2008, we completed the sale of substantially all of the assets of our wholly owned subsidiaries, QuadraMed International Pty Limited in Australia and QuadraMed International Limited in the United Kingdom for initial cash proceeds of \$0.1 million and future earn-out payments over a three-year period based on a schedule of targeted revenue between \$100,000 AUD and \$200,000 AUD per year. We recorded a loss on sale of assets of \$1.1 million in the second quarter of 2008. The products contained within these subsidiaries focused on stand-alone lab and radiology products installed in the United Kingdom, Australia and New Zealand. However, with the addition of the QuadraMed CPR ( QCPR ) product last year, which includes integrated lab and radiology, and our focus on the Care-Based Revenue Cycle and core products, these foreign-based products were considered redundant to our portfolio.

**7. EMPLOYMENT MATTERS**

On February 5, 2008, we announced a strategic initiative to increase overall product development capacity and to further accelerate delivery of our Care-Based Revenue Cycle product strategy to the healthcare market. Related to this capacity expansion and resource realignment initiative, we eliminated 69 positions in various technical, administrative and other non-technical areas. As a result, the Company incurred a one time severance cost for the nine month period ended September 30, 2008 of approximately \$0.5 million.

## Edgar Filing: QUADRAMED CORP - Form 10-Q

The reduction in force within the Software Development teams was tied to the strategic initiative to increase overall product development capacity and to further accelerate delivery of our Care-Based Revenue Cycle product strategy to the healthcare market through a partnering arrangement with Tata Consultancy Services ( TCS ). Although this refocusing of resources resulted in the elimination of 52 internal development positions, we currently have approximately 104 members of the Tata staff working on QuadraMed software development initiatives.

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)****8. FAIR VALUE MEASUREMENTS**

The Company adopted SFAS 157, *Fair Value Measurements*, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for financial instruments effective January 1, 2008. The framework requires the valuation of investments using a three tiered approach. The statement requires fair value measurement to be classified and disclosed in one of the following three categories:

Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;

Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability;

Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).

The following table represents the assets on our financial statements as of September 30, 2008 subject to SFAS 157, and indicates the fair value hierarchy of the valuation techniques we used to determine the fair value (in thousands):

Description	Balance at September 30, 2008	Fair Value Measurements at Reporting Date Using		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Commercial paper, certificates of deposit and other money market instruments	\$ 16,350	\$ 16,350	\$	\$
U.S. government and federal agency debt securities	3,533	3,533		
Auction rate securities	1,850		1,850	
Total	\$ 21,733	\$ 19,883	\$ 1,850	\$

The valuation of our auction rate securities were previously based on Level 3 measurements which consisted of values provided by our broker due to the uncertainty related to the liquidity in the auction rate security market. During the quarter ended September 30, 2008, the brokers who originally sold us the auction rate securities entered into agreements with state and/or federal regulators to repurchase certain auction rate securities at par value. The Company notified the brokers it would participate in the repurchase programs and in October 2008, \$1.2 million of our auction rate securities were sold at par under this program. The remaining \$0.7 million of our auction rate securities have been tendered for sale and our broker informed us the repurchase is expected to be completed in November 2008. We have the ability and intent to hold these securities Accordingly, we transferred our auction rate securities from Level 3 to Level 2 during the period. Management believes that there has been no impairment of the carrying value of these investments.

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)**

For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the period by investment type (in thousands):

Description	Level 3 Fair Value Measurements Three Months Ended September 30, 2008	
	Auction Rate Securities	Total
Beginning Balance	\$ 1,850	\$ 1,850
Total gains or losses (realized/unrealized):		
Included in earnings (or changes in net assets)		
Included in other comprehensive income		
Purchases, issuances and settlements		
Transfers in and/or out of Level 3	(1,850)	(1,850)
Ending Balance	\$	\$

Description	Level 3 Fair Value Measurements Nine Months Ended September 30, 2008	
	Auction Rate Securities	Total
Beginning Balance	\$	\$
Total gains or losses (realized/unrealized):		
Included in earnings (or changes in net assets)		
Included in other comprehensive income		
Purchases, issuances and settlements	(3,500)	(3,500)
Transfers in and/or out of Level 3	3,500	3,500
Ending Balance	\$	\$

**9. OTHER INTANGIBLE ASSETS**

Other intangible assets as of September 30, 2008 and December 31, 2007 were as follows (in thousands):

	As of September 30, 2008			As of December 31, 2007		
	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount	Gross Carrying Amount	Accumulated Amortization	Net Carrying Amount
Amortizable intangible assets						
Customer relationships	\$ 18,697	\$ (13,265)	\$ 5,432	\$ 18,749	\$ (12,378)	\$ 6,371

## Edgar Filing: QUADRAMED CORP - Form 10-Q

Trade names and other	3,842	(3,692)	150	3,985	(3,722)	263
Technology	16,748	(12,153)	4,595	20,153	(15,019)	5,134
<b>Total amortizable intangible assets</b>	<b>\$ 39,287</b>	<b>\$ (29,110)</b>	<b>\$ 10,177</b>	<b>\$ 42,887</b>	<b>\$ (31,119)</b>	<b>\$ 11,768</b>

Intangible assets are amortized over a period of two to ten years, which we believe to be the estimated useful lives of the individual assets.

Amortization of acquired technology, a component of other intangible assets, for the three months ended September 30, 2008 and 2007 was \$0.2 million and zero, respectively, and is included in cost of license revenue. Amortization expense other than for acquired technology for the three months ended September 30, 2008 and 2007

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)**

was \$0.3 million and \$0.3 million. Amortization of acquired technology, a component of other intangible assets, for the nine months ended September 30, 2008 and 2007 was \$0.8 million and \$0.8 million, respectively, and is included in cost of license revenue. Amortization expense other than for acquired technology for both of the nine month periods ended September 30, 2008 and 2007 was \$1.1 million. No impairment charges were recorded during the three or nine months ended September 30, 2008 or 2007.

On April 30, 2008, we completed the sale of substantially all of the assets of our wholly owned subsidiaries, QuadraMed International Pty Limited in Australia and QuadraMed International Limited in the United Kingdom. As a result, intangible assets in the amount of \$4.2 million, most of which were fully amortized, and accumulated amortization in the amount of \$3.8 million were included in our loss on sale of assets and removed from the values presented above.

We estimate that we will have the following amortization expense for the future periods indicated below (in thousands):

For the remaining three months ended December 31, 2008	\$ 573
For the years ended December 31,	
2009	2,276
2010	1,924
2011	1,684
2012	1,307
Thereafter	2,413
	\$ 10,177

**10. LINE OF CREDIT**

On December 5, 2006, we entered into a working capital line of credit agreement with our principal bank, under which we may borrow up to \$2.0 million. This credit facility is secured by 90-Day Certificates of Deposit. Borrowings under the line of credit bear interest at varying rates based on an independent index which is defined as the rate charged by the Lender on the underlying Certificates of Deposit plus a margin of 1.5%. The initial interest rate is established as 6.4% per annum. The line of credit has a stated maturity of March 23, 2009. There have been no borrowings, and there was no balance outstanding associated with this line of credit as of September 30, 2008 or as of December 31, 2007.

**11. SERIES A PREFERRED STOCK**

On September 17, 2004, QuadraMed issued 4.0 million shares of Series A Cumulative Mandatory Convertible Preferred Stock (the Series A Preferred Stock) in a private, unregistered offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933. The Series A Preferred Stock was sold for \$25 per share, and QuadraMed used the \$96.1 million of net proceeds of the offering to repurchase all of our Senior Secured Notes due 2008 and our 5.25% Convertible Subordinated 2005 Notes, together with accrued interest and related redemption premiums; the remainder was used for general corporate purposes.

The Series A Preferred Stock holders do not have any relative, participating, optional or other voting rights and powers, except that (i) if four quarterly dividend payments are in arrears, such holders are entitled to elect two substitute directors to the Board of Directors at any annual or special meeting, and (ii) in certain circumstances, such holders are entitled to vote on the authorization or creation of securities ranking on par with



**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

or above the Series A Preferred Stock, certain amendments to the Certificate of Incorporation or the Certificate of Designation for the Series A Preferred Stock and the incurrence of new senior indebtedness in an aggregate principal amount exceeding \$8 million. Prior to the authorization or creation of, or increase in the authorized amount of, any shares of any class or series (or any security convertible into shares of any class or series) ranking senior to or on par with the Series A Preferred Stock in the distribution of assets upon any liquidation, dissolution or winding up of QuadraMed or in the payment of dividends, QuadraMed must have the affirmative vote of a majority of any outstanding shares of the Series A Preferred Stock (along with any shares of every other series or class of common stock ranking on par with the Series A Preferred Stock having like voting rights). In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, before any payment or distribution of the Company's assets is made or set apart for the holders of common stock or any other class or series of shares of the Company's capital stock ranking junior to the Series A Preferred Stock as to the payment of dividends or as to the distribution of assets upon liquidation, dissolution or winding up, the holders of the Series A Preferred Stock shall be entitled to receive a liquidation preference of \$25 per share plus an amount equal to all dividends (whether or not earned or declared) accumulated, accrued and unpaid to the date of final distribution. However, for purposes of the foregoing provision, (1) a consolidation or merger of the Company with one or more entities, (2) a statutory share exchange or (3) a sale or transfer of all or substantially all of the Company's assets shall not be deemed to be a liquidation, dissolution or winding up of the Company.

The Series A Preferred Stock is entitled to quarterly dividends of \$0.34 (5.5% per annum) and is convertible into shares of common stock of the Company at a conversion price of \$15.50, equivalent to a conversion rate of 1.6129 shares of common stock for each share of Series A Preferred Stock. The Company has the right to demand conversion on or after May 31, 2007, in the event the volume weighted average of the daily market price per share during a period of 20 consecutive trading days equals or exceeds \$25.50.

Upon the conversion of shares of the Series A Preferred Stock to shares of common stock on or before September 1, 2007, the Series A Preferred Stock holders had an option to convert and receive, when declared by the Board of Directors, dividends equal to the total previously unpaid dividends payable from the effective date of conversion through September 1, 2007 at a rate of \$1.375 per annum, or 5.5% per annum, discounted to present value at a rate of 5.5% per annum, payable in cash or common shares or any combination thereof at the option of the Company. No shares were converted on or before the option date of September 1, 2007.

As a result of the aforementioned discounted dividend feature, at the date of issuance of the Series A Preferred Stock, the Company recorded dividends payable of \$15.2 million, which represents the present value of the three-year dividends. The present value adjustment of \$1.3 million was amortized over three years as interest expense using the effective interest rate method. The amortization period ended during 2007, and for the three and nine months ended September 30, 2007, approximately \$2,000 and \$50,000, respectively was recorded as interest expense.

The carrying value of the Series A Preferred Stock was also reduced by \$15.2 million, which represents the imputed discount on the Series A Preferred Stock and which is being accreted over three years using the effective interest rate method. The accretion period ended during 2007, and for the three months ended September 30, 2007, approximately \$1.3 million was accreted and charged to accumulated deficit. The Company determined that there was no beneficial conversion feature attributable to the Series A Preferred Stock.

**Table of Contents**

**QUADRAMED CORPORATION**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**  
**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**  
**(unaudited)**

The following table summarizes the Series A Preferred Stock activities (in thousands):

	As of September 30, 2008
Total issued	\$ 100,000
Less: Issuance cost	(3,856)
Less: Unaccreted discount	
Original present value of discount	(15,174)
2007 preferred stock accretion	2,854
2006 preferred stock accretion	5,059
2005 preferred stock accretion	4,796
2004 preferred stock accretion	2,465
Carrying value of preferred stock at September 30, 2008	\$ 96,144

**12. NET INCOME (LOSS) PER SHARE AND COMPREHENSIVE INCOME (LOSS)**

Basic income (loss) per share is determined using the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is determined using the weighted average number of common shares and common equivalent shares outstanding during the period. Common equivalent shares consist of shares issuable upon the exercise of stock options and warrants (using the treasury stock method) and conversion of the preferred stock (using the as-converted method). Common equivalent shares are excluded from the diluted computation if their effect is anti-dilutive.

The following common stock equivalent shares from the indicated equity instruments were considered in the calculation of diluted earnings per share (in thousands):

	Three months ended September 30, 2008      2007	
<i>Equity instruments:</i>		
Preferred stock	6,452	6,452
Warrants		412
Stock options	31	218
Total common stock equivalent shares	6,483	7,082

Nine months ended  
September 30,  
2008      2007

## Edgar Filing: QUADRAMED CORP - Form 10-Q

<i>Equity instruments:</i>		
Preferred stock	6,452	6,452
Warrants		413
Stock options	32	275
<b>Total common stock equivalent shares</b>	<b>6,484</b>	<b>7,140</b>

For the three month periods ended September 30, 2008, preferred stock equivalent shares were excluded from the computation of diluted earnings per share as their effect would be antidilutive. For the three month

Table of Contents

## QUADRAMED CORPORATION

## NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

## FOR THE QUARTER ENDED SEPTEMBER 30, 2008

(unaudited)

period ended September 30, 2007, common stock equivalent options, warrants and preferred stock equivalent shares were excluded from the computation of diluted earnings per share as their effect would be antidilutive. For the nine months ended September 30, 2008, the preferred stock equivalent shares were excluded from the diluted per share calculation as their effect would be antidilutive. For the nine months ended September 30, 2007, only the preferred stock equivalent shares were antidilutive and excluded from the calculation of diluted earnings per share.

The following table sets forth the computation of basic and diluted income (loss) per common share (in thousands):

	<b>Three months ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
<i>Numerator:</i>		
Net income (loss) attributable to common shareholders	\$ 1,094	\$ (522)
<i>Denominator:</i>		
Weighted average number of common shares outstanding:		
Basic	8,931	8,769
Diluted	8,962	8,769
Income (loss) per common share:		
Basic	\$ 0.12	\$ (0.06)
Diluted	0.12	(0.06)
	<b>Nine months ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
<i>Numerator:</i>		
Net income attributable to common shareholders	\$ 440	\$ 1,669
<i>Denominator:</i>		
Weighted average number of common shares outstanding:		
Basic	8,930	8,776
Diluted	8,963	9,464
Income per common share:		
Basic	\$ 0.05	\$ 0.19
Diluted	0.05	0.18

The components of QuadraMed's comprehensive income (loss) include the unrealized gain (loss) on available-for-sale securities and foreign currency translation adjustment. The following table sets forth the computation of comprehensive income (loss) (in thousands):

	<b>Nine months ended September 30,</b>	
	<b>2008</b>	<b>2007</b>
Net income attributable to common shareholders	\$ 440	\$ 1,669
Unrealized loss	4	23
Foreign currency translation adjustment	(420)	(5)

Comprehensive income

\$ 24

\$ 1,687

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**13. REVERSE STOCK SPLIT**

On June 16, 2008, QuadraMed Corporation announced the effectiveness of the reverse split of its common stock in the ratio of one-for-five (the Reverse Split). No fractional shares of common stock were issued as a result of the Reverse Split and stockholders received an insignificant cash payment in lieu of fractional shares. In connection with the reverse stock split, the Company transferred \$0.4 million from common stock to additional paid-in capital representing the par value of the original common shares outstanding prior to the one-for-five reverse stock split.

**14. STOCK-BASED COMPENSATION**

**Stock Incentive Plans**

We have issued stock options and restricted stock under the 1996 Stock Incentive Plan (the 1996 Plan), the 1999 Supplemental Stock Option Plan (the 1999 Plan), and the 2004 Stock Compensation Plan (the 2004 Plan), all of which were approved by stockholders. The 2004 Plan superseded the 1996 Plan, as amended, and the 1999 Plan, as amended, as of May 6, 2004, although stock options and restricted stock granted under the 1996 Plan and the 1999 Plan outstanding as of that date remain subject to the terms of those plans. Significant grants were made outside these plans pursuant to contracts with executives as an inducement to employment. Total non-plan stock options outstanding at September 30, 2008 were 231,427.

**1996 Stock Incentive Plan**

Under the 1996 Plan, the Board of Directors could have granted incentive and nonqualified stock options to employees, directors and consultants. The 1996 Plan was divided into the following five separate equity programs: (i) the discretionary option grant program under which eligible persons could have been, at the discretion of the plan administrator, granted options to purchase shares of common stock; (ii) the salary investment option grant program under which eligible employees could have elected to have a portion of their base salary invested each year in special option grants; (iii) the stock issuance program under which eligible persons could have been, at the discretion of the plan administrator, issued shares of common stock directly, either through the immediate purchase of such shares or as a bonus for services rendered to QuadraMed; (iv) the automatic option grant program under which eligible non-employee board members shall automatically received option grants at periodic intervals to purchase shares of common stock; and (v) the director fee option program under which non-employee board members could have elected to have all or any portion of their annual retainer fee otherwise payable in cash applied to a special option grant.

The exercise price per share for an incentive stock option could not have been less than the fair market value on the date of grant. The exercise price per share for a nonqualified stock option could not have been less than 85% of the fair market value on the date of grant. Option grants under the 1996 Plan generally expire 10 years from the date of grant and generally vest over a four-year period. Options granted under the 1996 Plan are exercisable subject to the vesting schedule. QuadraMed stockholders had authorized a total of 1,766,219 shares of common stock for grant under the 1996 Plan, of which 483,795 were outstanding at September 30, 2008. Because all shares remaining available for issuance under the 1996 Plan were transitioned into the 2004 Plan when the 2004 Plan was established, there were no shares available for grant under this plan at September 30, 2008.

---

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**1999 Supplemental Stock Option Plan**

In 1999, the QuadraMed Board of Directors approved the 1999 Plan. The 1999 Plan permitted non-statutory option grants to be made to employees, independent consultants and advisors who were not QuadraMed officers, directors or Section 16 insiders. The 1999 Plan was administered by the Board of Directors or its Compensation Committee and was scheduled to terminate in March 2009. The exercise price of all options granted under the 1999 Plan could not have been less than 100% of fair market value on the date of the grant. Options vested on a schedule determined by the Board of Directors or the Compensation Committee with a maximum option term of 10 years. QuadraMed stockholders had authorized a total of 684,849 shares of common stock, for grant under the 1999 Plan, of which 182,673 were outstanding at September 30, 2008. Because all shares remaining available for issuance under the 1999 Plan were transitioned into the 2004 Plan when the 2004 Plan was established, there were no shares available for grant under this plan at September 30, 2008.

**2004 Stock Compensation Plan**

On April 1, 2004, the QuadraMed Board of Directors approved the 2004 Plan. QuadraMed stockholders ratified the adoption of the 2004 Plan on May 6, 2004 at the QuadraMed 2004 Annual Meeting of Stockholders. The 2004 Plan replaced the 1996 Plan and 1999 Plan with respect to the unissued shares of common stock that were remaining in the 1996 Plan and the 1999 Plan on the date the 2004 Plan was ratified. Awards previously granted under the 1996 Plan and 1999 Plan remain subject to the terms of those plans. The QuadraMed stockholders initially authorized 307,274 shares of common stock for grant under the 2004 Plan and increased the number of shares available to the 2004 Plan by 600,000 shares at the 2007 Annual Meeting of Stockholders on September 7, 2007. As a result, the QuadraMed stockholders authorized a total of 907,274 shares of common stock, for grant under the 2004 Plan, of which, 793,259 were outstanding at September 30, 2008. There were 102,145 shares available for grant under this plan at September 30, 2008.

The 2004 Plan permits the grant of non-statutory options, incentive stock options, stock appreciation rights, restricted stock and restricted stock units to employees, prospective employees, directors, and advisors, consultants, and other individuals who provide services to QuadraMed. The exercise price of all options and stock appreciation rights granted under the 2004 Plan may not be less than 100% of fair market value on the date of the grant. The 2004 Plan also features a Non-Employee Director Option Grant Program, whereby non-employee members of the Board automatically receive grants of options with an exercise price of the fair market value per share of common stock as of the date the options are granted as of the date of our annual meetings of stockholders or upon their initial election or appointment to the Board. The Director Fee Option Grant Program, formerly a part of the 2004 Plan, was removed from the 2004 Plan after approval by the Company's stockholders at the 2008 Annual Meeting of Stockholders on June 5, 2008, in connection with the technical tax-related amendments to the 2004 Plan approved at that meeting. The Director Fee Option Grant Program provided for non-employee Board members to elect to have all or any portion of their annual cash retainer fee applied to special stock option grants with a below-market exercise price. The 2004 Plan is administered by the Compensation Committee and terminates in May 2014.

**Employee Stock Purchase Plans**

Our 2002 Employee Stock Purchase Plan (the 2002 Purchase Plan) was adopted by the Board of Directors in January 2002. A total of 140,690 shares of common stock were reserved for issuance under the 2002 Purchase Plan, pursuant to which eligible employees were able to contribute up to 10% of their compensation for the purchase of QuadraMed common stock at a purchase price of 85% of the lower of the fair market value of the

**Table of Contents****QUADRAMED CORPORATION****NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)****FOR THE QUARTER ENDED SEPTEMBER 30, 2008****(unaudited)**

shares on the first or last day of an offering period that may range from nine-months to forty-eight months, depending on the Company's stock price at certain intervals. Stock-based compensation expense relating to shares purchased on behalf of plan participants for the nine months ended September 30, 2008 and 2007 totaled \$33,840 and \$117,864, respectively.

Effective July 31, 2008, the 2002 Purchase Plan was terminated by the Board of Directors. On August 6, 2008, the Board of Directors adopted the 2008 Employee Stock Purchase Plan (the 2008 Purchase Plan) which became effective September 1, 2008 and 150,000 shares of common stock have been reserved for issuance under the 2008 Purchase Plan. The 2008 Purchase Plan is subject to shareholder approval at the Company's 2009 Annual Meeting of Stockholders.

***Stock Options:***

Stock options generally vest ratably over four years from the date of grant and terminate ten years from the date of grant. The exercise price of the options granted equaled or exceeded the market value of the common stock at the date of the grant. A summary of the stock option activity under all plans is as follows (in thousands except per share data):

	<b>Number of Shares</b>	<b>Weighted Average Exercised Price</b>
Options outstanding, January 1, 2008	1,738	\$ 18.15
Granted	173	9.40
Exercised	(47)	9.68
Cancelled	(172)	27.86
Options outstanding, September 30, 2008	1,692	\$ 14.31
Options exercisable, September 30, 2008	1,163	\$ 14.88

Stock-based compensation expense relating to stock options for the three months ended September 30, 2008 and 2007 totaled \$0.8 million and \$0.8 million, respectively, and \$2.4 million and \$1.5 million for the nine months ended September 30, 2008 and 2007, respectively.

The weighted average remaining contractual term and the aggregate intrinsic value for options exercisable at September 30, 2008 were 5.12 years and \$0.2 million, respectively. The weighted average remaining contractual term and the aggregate intrinsic value for options outstanding at September 30, 2008 were 6.18 years and \$0.2 million, respectively. As of September 30, 2008, unrecognized compensation expense related to stock options totaled approximately \$2.9 million, which will be recognized over a weighted average period of 1.2 years.

The fair value of each option grant is estimated on the date of the grant using the Black-Scholes Merton option-pricing model with the following assumptions:

**Nine Months Ended  
September 30,**

Edgar Filing: QUADRAMED CORP - Form 10-Q

	2008	2007
Expected dividend yield		
Expected stock price volatility	48.77%	85.97%
Risk-free interest rate	2.97%	4.20%
Expected life of options	5.39 years	5.30 years

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

The dividend yield of zero is based on the fact that the Company has never paid cash dividends on its common stock, and has no present intention of doing so. The risk-free interest rate is based on U.S. treasury yield curve in effect at the time of the grant for a term equivalent to the expected life of the option. The expected life and expected volatility are based on historical experience. The Company uses an estimated forfeiture rate of 17.9% for calculating stock-based compensation expense related to stock options and this rate is based on historical experience.

Based on the above assumptions, the weighted average estimated fair value of options granted during the three months ended September 30, 2008 and 2007 was \$3.62 and \$11.56 and \$4.27 and \$12.31 for the nine months ended September 30, 2008 and 2007, respectively. The weighted average estimated fair values for 2007 have been restated in accordance with the one-for-five reverse stock split effective in September 2008.

***Restricted Share Awards:***

The Company has issued, from time to time, common stock as restricted share awards, with a zero exercise price, as provided for under the QuadraMed stock compensation plans and other contractual commitments. The grants are generally made to certain senior executives. The majority of the restrictions lapse over three to four years. During the year ended December 31, 2005, we issued 130,000 shares of common stock as restricted stock; we issued no restricted stock subsequently through September 30, 2008. We record the fair value of the restricted shares on the date they are granted as deferred compensation within the Stockholders' Equity section of the consolidated balance sheets. Deferred compensation has been combined with additional paid-in capital as a result of the adoption of SFAS No. 123(R). The fair value of the restricted share award is amortized as compensation expense over the period in which the restrictions lapse. As of September 30, 2008, we had 110,000 restricted share awards subject to forfeiture at a weighted average grant date fair value of \$8.85 per share. During the three months ended September 30, 2008, 6,000 shares of restricted stock became fully vested. On July 17, 2008, the Board of Directors approved a policy under which the Company will offer to repurchase shares of restricted stock granted to the Company's employees on the date such shares vest; however, such repurchase shall be limited to an amount sufficient to permit the applicable employee to pay taxes on such shares. On October 17, 2008, the Company repurchased 46,420 shares of common stock from an executive officer for an aggregate purchase price of \$0.3 million pursuant to this policy.

Stock-based compensation expense relating to restricted share grants for each of the three month periods ended September 30, 2008 and 2007 was \$0.1 million and compensation expense was \$0.3 million for each of the nine month periods ended September 30, 2008 and 2007.

**15. MAJOR CUSTOMERS**

For the three and nine months ended September 30, 2008, sales to The Department of Veterans Affairs facilities accounted for approximately 14% and 17%, respectively, of our total revenues and sales to The County of Los Angeles accounted for approximately 11% of our total revenues during both periods. For the three and nine months ended September 30, 2007, sales to The Department of Veterans Affairs facilities accounted for approximately 22% and 19%, respectively, of our total revenues and sales to The County of Los Angeles accounted for approximately 10% and 12%, respectively, of our total revenues.

The Company is currently negotiating a renewal of its term license with the Department of Veterans Affairs for its fiscal year, which will end September 30, 2009. The Company is also currently permitting the Department of Veterans Affairs to continue its operation of the software while negotiations are being conducted, although the prior term expired on September 30, 2008.

**Table of Contents**

**QUADRAMED CORPORATION**

**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**FOR THE QUARTER ENDED SEPTEMBER 30, 2008**

**(unaudited)**

**16. INCOME TAXES**

Our income tax provision for interim periods is determined using an estimated annual effective tax rate adjusted for discrete items, if any, which are taken into account in the quarterly period in which they occur. We review and update our estimated annual effective tax rate each quarter. Our income tax expense totaled approximately \$1.6 million and \$0.1 million for the three months ended September 30, 2008 and 2007, respectively, and \$3.0 million and \$0.4 million for the nine months ended September 30, 2008 and 2007, respectively. These amounts represented effective income tax rates from continuing operations of approximately 40% and 9% for the three months ended September 30, 2008 and 2007, respectively, and 40% and 6% for the nine months ended September 30, 2008 and 2007, respectively. The significant change in our effective tax rate resulted from our having reduced the valuation allowance against most of our deferred tax assets in the year ended December 31, 2007, causing us to record income tax expense on our income from continuing operations as reported in our statement of operations for the three and nine months ended September 30, 2008. For the three and nine months ended September 30, 2007 we only recorded income tax expense related to the tax amortization of goodwill.

We implemented the provisions of FASB Interpretation No. 48 on January 1, 2007. There has been no material change to the amount of unrecognized tax benefits reported as of September 30, 2008. We are maintaining our historical method of accruing interest (net of related tax benefits) and penalties associated with unrecognized income tax benefits as a component of its income tax expense.

As of January 1, 2008 open tax years in major jurisdictions date back to 1994 due to the taxing authorities' ability to adjust operating loss and tax credit carryforwards. No changes in settled tax years have occurred through September 30, 2008. The Company does not anticipate a material change to its total amount of unrecognized tax benefits within the next 12 months.

**17. LITIGATION AND OTHER MATTERS**

We are subject to litigation in the normal course of business, but management does not believe that the resolution of any pending proceedings would have a material adverse effect on our company's financial position or results of operations.

**18. SUBSEQUENT EVENT**

On October 16, 2008, the Company repurchased 620,614 shares of its common stock from a group of commonly managed investment funds in a privately negotiated transaction for an aggregate purchase price of \$3.4 million. The aggregate purchase price was based upon a price per common share of \$5.50, which constituted a 37% discount to the average daily closing price of our common stock since it began trading on the Nasdaq Global Market, on July 9, 2008. The Company's Board of Directors determined that the repurchase was in the best interests of the Company and its stockholders. The Company repurchased the shares with existing cash on hand, and the repurchased shares were deposited into our treasury account. The shares repurchased represented approximately 7% of our outstanding common stock and all of our securities held by these shareholders.

**Table of Contents****Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations  
Cautionary Statement on Risks Associated With Forward-Looking Statements**

You should read the following discussion in conjunction with our Condensed Consolidated Financial Statements and related notes. This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties. The words believe, expect, target, goal, project, anticipate, predict, intend, plan, estimate, should, could, and similar expressions and their negatives are intended to identify such statements. Forward-looking statements are not guarantees of future performance, anticipated trends or growth in businesses, or other characterizations of future events or circumstances and are to be interpreted only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statement. You should not place undue reliance on these forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including the risks faced by us described below and elsewhere in this Quarterly Report on Form 10-Q, and in other documents we file with the SEC from time to time.

**Financial Statement Overview**

The Company has experienced a number of changes which affect the comparability of the period to period financial results. These changes include the acquisition of the CPR Business in late September 2007, which resulted in a significant revenue variance and additional headcount-related costs within our cost of services and software development expense categories in the 2008 periods. In addition, we began a strategic initiative during February 2008 to increase overall product development capacity through a partnering arrangement with Tata Consultancy Services (TCS). Concurrent with this partnering arrangement, we reduced our overall workforce by 69 employees, primarily in the service and software development areas, and incurred severance costs of \$0.5 million during 2008. These efforts are expected to result in more efficient operations over the long-term. We believe that these changes make it difficult to compare our operating results for the three and nine months ended September 30, 2008 and 2007.

On April 30, 2008, we completed the sale of substantially all of the assets of our wholly owned subsidiaries, QuadraMed International Pty Limited in Australia and QuadraMed International Limited in the United Kingdom for initial cash proceeds of \$0.1 million and future earn-out payments over a three-year period based on a schedule of targeted revenue between \$100,000 AUD and \$200,000 AUD per year. In connection with this sale, we recorded a loss on sale of these assets of \$1.1 million and severance expense of \$0.2 million, which are reflected primarily in costs of services in our second quarter of 2008. The products contained within these subsidiaries focused on stand-alone lab and radiology products installed in the United Kingdom, Australia and New Zealand. However, with the addition of the QuadraMed CPR (QCPR) product last year, which includes integrated lab and radiology, and our focus on the Care-Based Revenue Cycle and core products, these foreign-based products were considered redundant to our portfolio. We remain committed to our international clients with the QCPR product in Canada, the United Kingdom and Saudi Arabia.

On June 16, 2008, QuadraMed Corporation announced the effectiveness of the Reverse Split. On June 25, 2008 we received approval to list our common stock, par value \$0.01, on the NASDAQ Global Market under the new trading symbol of QDHC. We delisted our common stock from the American Stock Exchange on July 8, 2008 and our common stock began trading on the NASDAQ Global Market on July 9, 2008. We believe this change improves our corporate visibility and the effective marketability of our common stock, providing our investors with a better environment for trading shares of our common stock.

On July 5, 2008, the Saudi Arabia National Guard Health Affairs, located in Riyadh, Saudi Arabia, signed a contract for QCPR service expansion, migration to InterSystem's Cache database and interface licenses that represent sales bookings of approximately \$8.8 million, with a total contract value of approximately \$10.6 million. The revenue will be recognized on a percentage of completion basis over the contract service period, which is anticipated to be two years.

**Table of Contents**

On July 7, 2008, we announced the general availability of QCPR Cache/SQL 5.0.5, which provides hospitals with a fully integrated electronic health record operating on an enterprise platform built upon the InterSystems Cache, a high performance, post-relational SQL database that is consistently ranked best in KLAS.